BIO
Advancing malaria vaccine innovation through collaborative science
Developing effective malaria vaccines remains a major global health challenge. The parasite’s complex life cycle, shifting surface proteins and ability to evade immune responses make it far harder to target than viral pathogens. Progress relies on scientific depth, adaptable development strategies and strong biomanufacturing expertise.
Overcoming the unique complexity of malaria
Malaria vaccine design requires approaches that span multiple stages of the parasite’s lifecycle. Key challenges include:
- Selecting antigens that remain relevant across diverse strains
- Generating durable immune responses against a moving target
- Balancing scientific ambition with manufacturability
These demands increase development complexity and heighten the importance of dependable cGMP manufacturing services.
A partnership focused on scientific and technical progress
Recipharm Advanced Bio has collaborated with the University of Oxford since 2018, supporting malaria vaccine candidates from early development into GMP manufacture. Drawing on its capabilities as a biologics CDMO and advanced therapies CDMO, the team provides:
- Process development tailored to complex protein constructs
- Platforms that adapt to emerging data
- Biomanufacturing solutions that support clinical readiness
- Integrated analytical expertise
This collaborative model has helped advance multiple promising candidates, with two now progressing into clinical trials following encouraging early data. To learn more, read the full Q&A with the Recipharm team supporting this long-term programme.
